A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vaccinated with the fucose mannose ligand (FML)-vaccine of Leishmania donovani. A total of 97% of vaccinees were seropositive to FML and 100% showed intradermal reaction to L. donovani lysate, 7 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls (ANOVA, P<0.0001). After 2 years, 92% (chi(2)=6.996; P<0.0025) protection was achieved: only 8% of vaccinees showed mild signs of kala-azar with no deaths while 33% of controls developed clinical or fatal disease. The FML-vaccine induced a significant, long-lasting and strong protective effect against canine kala-azar in the field.
da Silva
V O
VO
Instituto de Microbiologia, 'Prof. Paulo de Góes', Cidade Universitária, CCS, Universidade Federal do Rio de Janeiro (UFRJ), CP 68040, Ilha do Fundão, CEP 21941-590, Rio de Janeiro, Brazil.
Borja-Cabrera
G P
GP
Correia Pontes
N N
NN
de Souza
E P
EP
Luz
K G
KG
Palatnik
M
M
Palatnik de Sousa
C B
CB
D000818:Animals; D001938:Brazil; D004285:Dogs; D037102:Lectins / Q000276:immunology*; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D016052:Protozoan Vaccines / Q000276:immunology*; D014611:Vaccination; D015047:Zoonoses
D037102:Lectins; D016052:Protozoan Vaccines; C027112:fucose-binding lectin